Javascript must be enabled to continue!
EFFECT OF IRBESARTAN ON THE BURDEN OF ATRIAL FIBRILLATION IN THE HYPERTENSIVE PATIENTS WITH BRADYCARDIA-TACHYCARDIA SYNDROME UNDERGOING CARDIAC PACEMAKER IMPLANTATION
View through CrossRef
Objectives
To evaluate the effect of irbesartan, an angiotensin-receptor blocker, on the prevention of paroxysmal atrial fibrillation in the hypertensive patients with sick sinus syndrome and paroxysmal atrial fibrillation.
Methods
336 patients diagnosed with hypertension, sick sinus syndrome and paroxysmal atrial fibrillation, were prospectively enrolled. After implanted with dual-chamber pacemakers, they were randomly divided into two groups according to their treatments to hypertension were irbesartan (Gi, n=189) or nifedipine (Gn, n=147). The patients were followed up for one year, the maximum P wave duration (Pmax), the P wave dispersion (Pd), the cardiac remodelling, the data of automatic mode switch(AMS) and the total burden of atrial fibrillation were estimated, and the results were statistically analysed and compared between two groups.
Results
The basic clinical characteristics of two groups, including echocardiological parameters, were comparable. One year later, no significant differences in the mean reduction both in systolic and in diastolic blood pressure were found in two groups, and the differences of Pmax were not remarkable too(122±7.6ms vs 124±8.1 ms, p>0.05). However, the increase of Pd in Gi was statistically lower than that in Gn (26.3±4.5 ms vs 32.1±5.2 ms, p<0.05). Moreover, though chocardiograms demonstrated that there were no apparently differences in left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV) and left ventricular ejection fraction (LVEF) in two groups, the diameters of right atrium (RA) and left atrium (LA) in Gi were significantly smaller than that in Gn (RA: 25.2±3.6 mm vs 27.5±4.3 mm, LA: 33.8±4.2 mm vs.39.5±5.1 mm, p all<0.05). Compared with those in Gn, the frequencies of AMS in Gi decreased more sharply (202±45 times vs 162±48 times, p<0.05), the duration of AMS shortened more apparently (291±68 h vs. 212±72 h, p<0.05), the total burden of atrial fibrillation eased more obviously (25.8±5.3% vs. 24.2±4.3%, p<0.05).
Conclusions
Irbesartan, a conventional treatment to hypertension, additionally contributes to coordinate the anisotropy of double atrial depolarization, shortens the duration of atrial fibrillation, consequently leading to reducing the total burden of atrial fibrillation.
Title: EFFECT OF IRBESARTAN ON THE BURDEN OF ATRIAL FIBRILLATION IN THE HYPERTENSIVE PATIENTS WITH BRADYCARDIA-TACHYCARDIA SYNDROME UNDERGOING CARDIAC PACEMAKER IMPLANTATION
Description:
Objectives
To evaluate the effect of irbesartan, an angiotensin-receptor blocker, on the prevention of paroxysmal atrial fibrillation in the hypertensive patients with sick sinus syndrome and paroxysmal atrial fibrillation.
Methods
336 patients diagnosed with hypertension, sick sinus syndrome and paroxysmal atrial fibrillation, were prospectively enrolled.
After implanted with dual-chamber pacemakers, they were randomly divided into two groups according to their treatments to hypertension were irbesartan (Gi, n=189) or nifedipine (Gn, n=147).
The patients were followed up for one year, the maximum P wave duration (Pmax), the P wave dispersion (Pd), the cardiac remodelling, the data of automatic mode switch(AMS) and the total burden of atrial fibrillation were estimated, and the results were statistically analysed and compared between two groups.
Results
The basic clinical characteristics of two groups, including echocardiological parameters, were comparable.
One year later, no significant differences in the mean reduction both in systolic and in diastolic blood pressure were found in two groups, and the differences of Pmax were not remarkable too(122±7.
6ms vs 124±8.
1 ms, p>0.
05).
However, the increase of Pd in Gi was statistically lower than that in Gn (26.
3±4.
5 ms vs 32.
1±5.
2 ms, p<0.
05).
Moreover, though chocardiograms demonstrated that there were no apparently differences in left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV) and left ventricular ejection fraction (LVEF) in two groups, the diameters of right atrium (RA) and left atrium (LA) in Gi were significantly smaller than that in Gn (RA: 25.
2±3.
6 mm vs 27.
5±4.
3 mm, LA: 33.
8±4.
2 mm vs.
39.
5±5.
1 mm, p all<0.
05).
Compared with those in Gn, the frequencies of AMS in Gi decreased more sharply (202±45 times vs 162±48 times, p<0.
05), the duration of AMS shortened more apparently (291±68 h vs.
212±72 h, p<0.
05), the total burden of atrial fibrillation eased more obviously (25.
8±5.
3% vs.
24.
2±4.
3%, p<0.
05).
Conclusions
Irbesartan, a conventional treatment to hypertension, additionally contributes to coordinate the anisotropy of double atrial depolarization, shortens the duration of atrial fibrillation, consequently leading to reducing the total burden of atrial fibrillation.
Related Results
e0188 Enalapril, Irbesartan and Ang-(1-7) prevent atrial tachycardia-induced sodium channel remodelling
e0188 Enalapril, Irbesartan and Ang-(1-7) prevent atrial tachycardia-induced sodium channel remodelling
Purpose
Recent studies indicated that the activation of renin-angiotensin system (RAS) played an important role in the development and recurrence of atrial fibril...
Atrial Flutter, The Commonly Misdiagnosed Arrhythmia as Supraventricular Tachycardia or Sinus Tachycardia
Atrial Flutter, The Commonly Misdiagnosed Arrhythmia as Supraventricular Tachycardia or Sinus Tachycardia
Background: Atrial flutter is a common arrhythmia in structurally normal or abnormal heart. The electrocardiographic features of it can be mistaken for sinus tachycardia or suprave...
Adiponectin and Lone atrial fibrillation
Adiponectin and Lone atrial fibrillation
Objective: Lone atrial fibrillation is an idiopathic arrhythmia seen in younger individuals without any secondary disease. Adiponectin is an endogenous adipocytokine that increases...
ASSA13-03-9 Decreased Expression of Small-Conductance Ca2+-Activated K+ Channels SK1, SK2, and SK3 in Patients with Persistent Atrial Fibrillation
ASSA13-03-9 Decreased Expression of Small-Conductance Ca2+-Activated K+ Channels SK1, SK2, and SK3 in Patients with Persistent Atrial Fibrillation
Background
Small-conductance Ca2+-activated K+ channels (SK channels) have been reported involved in atrial fibrillation (AF) as a new ion channel candidates, as ...
RELATIONSHIP BETWEEN ATRIAL FIBRILLATION CARDIOVERSION AND F
RELATIONSHIP BETWEEN ATRIAL FIBRILLATION CARDIOVERSION AND F
Objectives
To investigate the relationship between atrial fibrillation cardioversion and f wave in electrocardiogram, providing an ordinary and noninvasive method...
Method Development and Validation of Irbesartan by RP-HPLC
Method Development and Validation of Irbesartan by RP-HPLC
A simple, sensitive, rapid and selective isocratic reversed phase High Performance Liquid Chromatographic (HPLC) method has been developed for Irbesartan from bulk drug using a mob...
Incidence of Atrial fibrillation in patient with Permanent pacemaker
Incidence of Atrial fibrillation in patient with Permanent pacemaker
Background: Atrial fibrillation (AF) is a common cardiac arrhythmia linked to significant morbidity, particularly in pacemaker patients. Pacemakers, crucial for managing bradycardi...
Abstract 15372: The Lewis Lead
Abstract 15372: The Lewis Lead
The Lewis lead is a modified ECG configuration that can enhance the amplitude of the atrial electrical activity and is useful when the atrial activity cannot be discerned in the st...

